IGC Pharma (IGC) Share-based Compensation (2011 - 2025)
IGC Pharma (IGC) reported Share-based Compensation of $4.7 million for Q2 2025, up 1069.15% year-over-year from $402000.0 in Q2 2024, and up 932.97% quarter-over-quarter from $455000.0 in Q1 2025.
IGC Pharma (IGC) Share-based Compensation (2011 - 2025) Analysis & Trends
IGC Pharma (IGC) has 15 years of Share-based Compensation data on file, last reported at $4.7 million in Q2 2025.
- Share-based Compensation for Q2 2025 came in at $4.7 million, up 1069.15% year-over-year; the trailing twelve-month figure through Sep 2025 was $5.5 million (up 231.5% YoY), and the FY2026 annual result was $4.0 million, down 6.98% from the prior year.
- Share-based Compensation grew to $4.7 million in Q2 2025 per IGC's latest filing, from $455000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $4.7 million in Q2 2025 and troughed at $125000.0 in Q2 2021.
- A 5-year average of $738222.2 and a median of $469500.0 in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation sank 69.01% in 2023, then jumped 1069.15% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $523000.0 in 2021, then retreated by 7.46% to $484000.0 in 2022, then climbed by 8.68% to $526000.0 in 2023, then dropped by 27.57% to $381000.0 in 2024, then soared by 1133.6% to $4.7 million in 2025.
- Business Quant data shows IGC's Share-based Compensation at $4.7 million in Q2 2025, $455000.0 in Q1 2025, and $381000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 26.47 Mn |
| 10 | IGC Pharma | 29.33 Mn | 29.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 4.70 Mn |
| Jun 30, 2025 | 4.70 Mn |
| Mar 31, 2025 | 455,000.00 |
| Mar 31, 2025 | 455,000.00 |
| Dec 31, 2024 | 381,000.00 |
| Dec 31, 2024 | 381,000.00 |
| Sep 30, 2024 | 402,000.00 |
| Sep 30, 2024 | 402,000.00 |
| Jun 30, 2024 | 402,000.00 |
| Jun 30, 2024 | 402,000.00 |
| Mar 31, 2024 | 340,000.00 |
| Mar 31, 2024 | 340,000.00 |
| Dec 31, 2023 | 526,000.00 |
| Dec 31, 2023 | 526,000.00 |
| Sep 30, 2023 | 550,000.00 |
| Sep 30, 2023 | 550,000.00 |
| Jun 30, 2023 | 357,000.00 |
| Jun 30, 2023 | 357,000.00 |
| Mar 31, 2023 | 583,000.00 |
| Mar 31, 2023 | 583,000.00 |